Publication Date:
2017-10-26
Description:
Resistance to checkpoint blockade therapy through inactivation of antigen presentation Nature Communications, Published online: 26 October 2017; doi:10.1038/s41467-017-01062-w Resistance to immune-checkpoint blockade often occurs in treated patients. Here, the authors demonstrate that B2M loss is a mechanism of primary and acquired resistance to therapies targeting CTLA4 or PD-1 in melanoma patients.
Electronic ISSN:
2041-1723
Topics:
Biology
,
Chemistry and Pharmacology
,
Natural Sciences in General
,
Physics
Permalink